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Summary
A predominance of small, dense low-density
lipoproteins (LDL) has been accepted as an emerg-
ing cardiovascular risk factor by the National
Cholesterol Education Program Adult Treatment
Panel III. LDL size seems to be an important
predictor of cardiovascular events and progression
of coronary heart disease and evidences suggests
that both quality (particularly small, dense LDL)
and quantity may increase cardiovascular risk.
However, other authors have suggested that LDL
size measurement does not add information beyond
that obtained by measuring LDL concentration,
triglyceride levels and HDL concentrations. There-
fore, it remains debatable whether to measure LDL
particle size in cardiovascular risk assessment and, if
so, in which categories of patient. Therapeutic
modulation of LDL particle size or number appears
beneficial in reducing the risk of cardiovascular
events, but no clear causal relationship has been
shown, because of confounding factors, including
lipid and non-lipid variables. Studies are needed to
investigate the clinical significance of LDL size
measurements in patients with coronary and non-
coronary forms of atherosclerosis; in particular, to
test whether LDL size is associated with even higher
vascular risk, and whether LDL size modification
may contribute to secondary prevention in such
patients.
Introduction
Cardiovascular diseases are still the primary cause
of death in most industrialized countries. Effective
prevention includes treatment of a series of risk
factors: smoking, hypertension, diabetes, obesity,
and dyslipidaemia, which includes elevated trigly-
cerides, total and low-density-lipoprotein (LDL)
cholesterol levels, as well as lowered high-density-
lipoprotein (HDL) cholesterol.1
The therapeutic modulation of distinct LDL
subspecies is also of great benefit in reducing the
risk of cardiovascular events.1–3 The peak size of
LDL in humans shows a bimodal (rather than a
normal) distribution, and can be separated into two
phenotypes that differ in size, density, physico-
chemical composition, metabolic behaviour and
atherogenicity. These phenotypes have been called
‘pattern A’ (larger, more buoyant LDL) and ‘pattern
B’ (smaller, denser LDL predominate).2–5
LDL size correlates positively with plasma HDL
levels and negatively with plasma triglyceride con-
centrations, and the combination of small, dense
LDL, decreased HDL cholesterol and increased
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triglycerides has been called the ‘atherogenic
lipoprotein phenotype’6 (Figure 1). This partly
heritable trait is a feature of the metabolic syndrome,
and is associated with increased cardiovascular risk.
LDL size seems to be an important predictor of
cardiovascular events and progression of coronary
artery disease, and a predominance of small, dense
LDL has been accepted as an emerging cardio-
vascular risk factor by the National Cholesterol
Education Program Adult Treatment Panel III.1
However, other authors have suggested that LDL
subclass measurement does not add independent
information to that conferred by the simple LDL
concentration, along with the other standard risk
factors.7 Thus it remains debatable whether to
measure LDL particle size for cardiovascular risk
assessment, and if so, in which categories of
patients.
LDL size and environmental/
genetic influence
The prevalence of the pattern B phenotype is
approximately 30% in adult men, 5–10% in young
men and women 520 years, and approximately
15–25% in post-menopausal women.2,3 LDL size is
genetically influenced, with a heritability ranging
from 35–45%, based on an autosomal dominant
or codominant model with varying additive
and polygenic effects.8 Clearly, non-genetic and
environmental factors influence the expression of
this phenotype, and abdominal adiposity and oral
contraceptive use are both associated with an
increase in small, dense LDL.9–11
Dietary factors are also important. A very low-fat
high-carbohydrate diet can induce pattern B in
people who are genetically predisposed to this
phenotype.12 In addition, the predominance of
small, dense LDL is commonly found in conjunction
with familial disorders of lipoprotein metabolism
that are associated with increased risk of premature
coronary artery disease, including familial combined
hyperlipidaemia, hyper-beta-lipoproteinaemia and
hypo-alpha-lipoproteinaemia.2
LDL size measurement
Particle size distribution of plasma LDL subfractions
may be measured by different laboratory techni-
ques,7 but the most common procedure is 2–16%
gradient gel electrophoresis at 10C using a Tris
(0.09M)-boric acid (0.08 M)-Na2EDTA (0.003M)
buffer (pH 8.3).9,13 Plasma is adjusted to 20%
sucrose, and 3–10 ml are applied to the gel. Potentials
are set at 40mV (15min), 80mV (15min), and
125mV (24 h). Gels are fixed and stained for
lipids in a solution containing oil red O in 60%
ethanol at 55C, and for proteins in a solution
containing 0.1% Coomassie brilliant blue R-250,
50% ethanol and 9% acetic acid, and then
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Figure 1. LDL heterogeneity and plasma triglyceride and HDL cholesterol concentrations (modified from reference 3).
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scanned with a densitometer. Molecular diameters
are determined on the basis of migration distance, by
comparison with standards of known diameter.9,13
Assignment of LDL subclass phenotypes is based
on the particle diameter of the major plasma LDL
peak. LDL phenotype A (larger, more buoyant LDL)
is defined as an LDL subclass pattern with the
major peak at a particle diameter of 258 A˚ or greater,
whereas the major peak of LDL phenotype B
(small, dense LDL) is at a particle diameter of
5258 A˚2,3,9,14 (Figures 2 and 3).
Atherogenicity of small, dense LDL
Several reasons have been suggested for the ather-
ogenicity of small, dense LDL. Smaller, denser
LDL are more easily taken up by arterial tissue than
are larger LDL,15 suggesting greater transendothelial
transport of smaller particles. In addition, smaller
LDL particles may also have decreased receptor-
mediated uptake and increased proteoglycan bind-
ing.16 Sialic acid, perhaps because of its exposure
at the LDL surface, plays a determinant role in the
in vitro association of LDL with the polyanionic
proteoglycans,17 and the sialic acid content of LDL
particles is lower in subjects with the pattern B
phenotype.
Oxidative susceptibility increases and antioxidant
concentrations decrease with decreasing LDL size.18
The altered properties of the surface lipid layer
associated with a reduced content of free choles-
terol19 and increased content of polyunsaturated
fatty acids20 might also contribute to the enhanced
oxidative susceptibility of small, dense LDL.
Recently,21 we chose apoB transgenic mice to
evaluate the kinetic behaviour of human LDL
particles of different size in vivo in a genetically
homogeneous recipient, thus avoiding other meta-
bolic differences that could influence LDL
metabolism. We found that small LDL particles
had intrinsic features that led to retarded metabolism
and decreased intra/extravascular equilibration
compared to medium-sized LDL; these properties
could contribute to the greater atherogenicity of
small, dense LDL.
Association of LDL size with
cardiovascular events and
disease progression
The magnitude and independence of the association
of LDL size with cardiovascular diseases has been
tested in many studies, including cross-sectional
and prospective epidemiological studies, as well as
clinical intervention trials.22–72 (Table 1). The vast
majority (but not all) show a significant univariate
association of small, dense LDL with increased
coronary heart disease (CHD) risk. However,
LDL size is seldom a significant and independent
predictor of CHD risk after multivariate adjustment
for confounding variables, in particular plasma
triglyceride levels and HDL cholesterol concentra-
tions (Table 1).
Therefore, it may be that the increased risk
associated with smaller LDL size in univariate
analyses is a consequence of the broader patho-
physiology of which small, dense LDL is a part (e.g.
high triglycerides, low HDL cholesterol, increased
LDL particle number, obesity, insulin resistance,
diabetes, metabolic syndrome), rather than a reflec-
tion of an intrinsic increased atherogenic potential.
A clear causal relationship between small dense
LDL and increased cardiovascular risk cannot be
proven, based on our present knowledge.
This is further complicated by the fact that at the
same level of LDL cholesterol, higher-risk pattern B
individuals have significantly more particles than
those with pattern A. The number of LDL particles
in plasma is potentially important, because the
arterial walls are exposed to these particles, and an
increased number might increase atherogenicity
independently of particle size.73 Is the higher risk
of pattern B individuals attributable to the fact that
they have more LDL particles in total, or does
the smaller size contribute independently to CHD
risk?
Assessment of LDL particle size by gradient gel
electrophoresis does not provide information about
the concentration or number of small, dense LDL
particles, which has been historically estimated
by measuring apo B concentrations.74 Rader75 and
Sniderman76 reviewed 32 trials that studied the
relationship between plasma apo B concentrations
and CHD risk, but the data did not consistently
support a stronger association between CHD risk
and apo B then between CHD and other lipid
parameters.
LDL particle number is currently assessed by
nuclear magnetic resonance, which provides data
on both LDL particle size and concentration.77
Higher LDL particle concentrations seem to be
important in determining CHD risk,78,79 but few
studies have assessed whether the quantity rather
than the size of small, dense LDL is more strongly
associated with CHD risk.55–57,72 In these studies,
the number of total and smaller LDL particles
was a significant and independent predictor of
CHD risk, after multivariate adjustment for lipid
variables55–57,72 (Table 1).
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Figure 3. Densitometric scan of lipid-stained 2–16% nondenaturing gradient gel electrophoresis of whole plasma from a
subject with a predominance of small, dense LDL (LDL phenotype ‘pattern B‘).
Figure 2. Densitometric scan of lipid-stained 2–16% non-denaturing gradient gel electrophoresis of whole plasma from a
subject with a predominance of large, buoyant LDL (LDL phenotype ‘pattern A‘).
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In addition, studies that measured not only LDL
cholesterol concentration and particle size, but also
LDL particle numbers in plasma, have provided
important information on the risk of CHD.73,77
When both number of LDL particles and LDL size
are measured in the same study population, small,
dense LDL particles are frequently not significantly
associated with CHD risk.34,36,41,56,57 (Table 1).
These data underline the clinical importance of
assessing LDL particle number in establishing the
risk of CHD associated with the presence of small,
dense LDL particles.74,77
LDL size and acute myocardial
infarction
Acute myocardial infarction and the atherogenic
lipoprotein phenotype seem to share a similar
array of interrelated metabolic aberrations, includ-
ing modifications in plasma lipids and lipoproteins
as well as a relative resistance to insulin-mediated
glucose uptake. The common lipid alterations
observed during the acute phase of myocardial
infarction include a rise in triglyceride levels
and a fall in total, LDL and HDL cholesterol
concentrations80–82 and such modifications have
a great clinical relevance, since they must be taken
into account in making therapeutic decisions.83
However, despite the data regarding modifica-
tions of total plasma lipoprotein fractions during
a myocardial infarction, it is less certain whether
LDL peak particle size is also modified in the acute
phase, and therefore what the best time is to
measure it. In a group patients admitted to hospital
for a myocardial infarction, and followed until
discharge and 3 months after the event, reduction
of LDL peak particle size was premature and
persisted during the hospitalization, with a signifi-
cant increase 3 months after the myocardial infarc-
tion.84 In addition, the timing of these changes
seemed to precede those of all other lipoproteins.
Table 1 Univariate and multivariate analyses on the association of size or number of small, dense LDL particles with
cardiovascular diseases
Author Study design Univariate Multivariate Author Study design Univariate Multivariate
LDL size
Crouse22 CS Y N Skoglund47 CS Y Y
Austin23 CS Y N Zambon48 P Y Y
Griffin24 CS Y N Austin49 P Y N
Tornvall25 CS Y – Hulthe50 CS N –
Campos26 CS Y N Hulthe51 CS Y –
Coresh27 CS Y N Bokemark52 CS Y N
Griffin28 CS Y Y Campos53 P N N
Campos29 CS N N Kamigaki54 CS Y N
Sherrard30 CS N – Rosenson55 P Y Y
Rajman31 CS N – Blake56 P Y N
Stampfer32 P Y N Kuller57 P Y N
Gardner33 P Y Y Liu58 CS Y Y
Miller34 P Y N Koba59 CS Y Y
Mack35 P Y N Vakkilainen60 P Y N
Lamarche36 P Y Y Slowik61 CS Y –
Gray37 CS N – Hallman62 CS Y –
Wahi38 CS N – Watanabe63 CS Y –
Slyper39 CS N – Wallenfeldt64 P Y –
Freedman40 CS Y N Kullo65 CS Y N
Ruotolo41 P Y N van Tits66 P Y –
O’Neal42 CS Y Y Inukai67 CS Y Y
Landray43 CS Y N Mohan68 CS Y –
Hulthe44 CS Y – Yoon69 CS Y Y
Mykkanen45 P N N St Pierre70 P Y –
Erbey46 CS Y N Berneis71 CS Y Y
LDL number
Rosenson55 P Y Y Kuller57 P Y Y
Blake56 P Y Y Otvos72 P Y Y
CS, cross-sectional; P, prospective; Y, yes; N, no.
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Even angina itself (against a background of
coronary artery spasm), without atherosclerosis,
may lower LDL size.85
LDL size and vascular disease
According to the National Cholesterol Education
Program Adult Treatment Panel III, clinical forms
of non-coronary atherosclerosis carry a risk for
CHD equal to those with established CHD.1 These
conditions include peripheral arterial disease,
symptomatic (transient ischaemic attack or stroke
of carotid origin) and asymptomatic (450% stenosis
on angiography or ultrasound) carotid artery disease
and abdominal aortic aneurysm.1
However, despite plentiful data on the relationship
between LDL size and atherosclerosis in patients with
CHD, very few authors have investigated such
relationships in patients with non-coronary forms of
atherosclerosis, and studies with larger number of
patients are needed. But the available data suggest
a strong association between small, dense LDL and
non-coronary forms of atherosclerosis.
Smaller, denser LDL particles are a risk factor for
peripheral arterial disease, whether in the absence
or presence of diabetes.42 In some studies, common
features of peripheral arterial disease are repre-
sented by increased triglyceride levels and lower
HDL cholesterol concentrations,42 and patients with
such lipid abnormalities mostly have atherogenic
small, dense LDL particles.6,86
The association between carotid disease and
small, dense LDL has been found in healthy
subjects43,47,51,52,62 as well as in various categories
of patients (familial combined hyperlipidemia,
familial hypercholesterolemia, vascular dementia,
Alzheimer’s disease, insulin resistance or type 2
diabetes).44,58,63,66,71 It has also been recently
suggested that carotid atherosclerosis regression
or progression may be linked to LDL size.64,66
No published studies have directly examined
the association of LDL size with the presence of
abdominal aortic aneurysms. However, patients
with abdominal aortic aneurysms show an elevated
prevalence of the metabolic syndrome,87 which is
associated with the predominance of small, dense
LDL,2,3,6 and therefore such patients are likely to
have reduced LDL size.
Clinical value of therapeutic
modification of LDL size
Hypolipidaemic treatment can alter LDL subclass
distribution, and statins and fibrates are currently
the most widely used lipid-lowering agents. Statins
are potent inhibitors of hydroxy-methyl-glutaryl-
coenzyme A reductase, the rate-limiting enzyme in
hepatic cholesterol synthesis, and are the primary
drugs of choice for the treatment of elevated plasma
LDL cholesterol concentrations.74 Fibrates have a
major impact on triglyceride metabolism, mediated
by peroxisomal proliferation activator receptors
(PPAR) and through stimulation of lipoprotein
lipase.88
Statins potentially lower large, medium and small
LDL particles, but with wide variation between
the different agents. Treatment with pravastatin
favourably altered LDL size in four studies,89–92
but not in others.93–104 Similarly, simvastatin therapy
showed significant,105–110 moderate111,112 or no
effect113–124 on LDL subclasses. Fluvastatin and
atorvastatin seem to be more effective: fluvastatin
favourably altered LDL size in six studies,125–130
but not in two; 131,132 treatment with atorvastatin
was more often beneficial104,109,133–148 than
not.124,149–158 Promising data were also recently
published on the use of rosuvastatin.159
Fibrates seem to have more effect than statins
on LDL size. Therapy with fenofibrate, bezafibrate
and gemfibrozil usually results in a beneficial
effect,100,101,107,109,117,118,145,149,151,160–176 with
very rare negative findings.113,177
As already reported,88 although not directly
demonstrated, modulation of LDL size with fibrates
probably contributed to the reduction of CHD risk
in the Helsinki Heart Study and in the Veterans
Affairs High-Density Lipoprotein Cholesterol Inter-
vention Trials Study Group.178–180 It is also likely
that there was a bias towards small LDL in clinical
trials that showed cardiovascular benefit from
statins.181–183
Other studies have investigated whether thera-
peutic modification of LDL particle size and number
reduces cardiovascular risk, using arteriographic
changes as outcome variables. CAD progression in
the controls is significantly greater in patients with
a predominance of small, dense LDL,35,184 and
arteriographic benefit is concentrated in patients
with a predominance of small, dense LDL who
receive treatment that tends to lower it. These
studies included the Stanford Coronary Risk
Intervention Project, the Familial Atherosclerosis
Treatment Study (FATS), the St Thomas’
Atherosclerosis Regression Study (STARS) and the
Pravastatin Limitation of Atherosclerosis in the
Coronary Arteries (PLAC-I) trial.34,48,55,185
In all of these studies, therapeutic modulation of
LDL size was significantly associated with reduced
CHD risk on univariate analysis. Under multivariate
analysis with adjustments for confounding factors,
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changes in LDL size by drug therapy were the best
correlates of changes in coronary stenosis in FATS,48
and the smallest LDL fraction was the plasma
lipoprotein subfraction with the single most power-
ful effect on CAD regression in middle-aged men
with hypercholesterolaemia in STARS.185
In PLAC-I, using a logistic regression models that
adjusted for lipid levels and other confounding
factors, elevated levels of small LDL were associated
with a nine-fold increased risk of CAD progression,
but only in the placebo group.55 In addition, in this
study, elevated LDL particle number was a predictor
of CAD progression after adjustment for race, sex,
age, treatment group, baseline lumen diameter and
plasma lipids.55
All these data suggest that the therapeutic
modification of LDL size, or number of small LDL
particles, is significantly associated with reduced
cardiovascular risk, even after multivariate adjust-
ment for confounding factors. However, whether
LDL size or number of LDL particles is more
(or equally) important can not be concluded from
the current evidence.
Conclusions
Genetic and environmental factors influence the
expression of small, dense LDL, which is not
completely independent of traditional lipids, corre-
lating negatively with plasma HDL concentrations
and positively with plasma triglyceride levels.
Small, dense LDL are associated with the metabolic
syndrome, and with increased risk for cardio-
vascular disease and diabetes mellitus.
LDL size also seems to be an important predictor
of cardiovascular events, and progression of
coronary artery disease and a predominance of
small, dense LDL has been accepted as an emerging
cardiovascular risk factor by the National Choles-
terol Education Program Adult Treatment Panel III.1
However, other authors have suggested that LDL
subclass measurement does not add independent
information to that conferred generically by the LDL
concentration along with the other standard risk
factors.8 The number, rather than the density, of LDL
particles may be a stronger predictor of CHD.71
Therefore, remains debatable whether to measure
LDL particle size in cardiovascular risk assessment,
and if so, in which categories of patients. In several
studies, therapeutical modulation of LDL particle
size or number has been of great benefit in reducing
the risk of cardiovascular events, but a no clear
causal relationship has been shown, due to con-
founding factors, including lipid and non-lipid
variables. Additional studies are needed to
investigate the clinical significance of LDL size
measurement.
Recently, the Coordinating Committee of the
National Cholesterol Education Program stated that
very high-risk patients may benefit from more
aggressive therapeutic approaches.186 Screening
for the presence of small, dense LDL in patients
with coronary or non-coronary forms of athero-
sclerosis may identify those with even higher
vascular risk, and assist in the targeting of appro-
priate treatment.
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